Family Experiences After International Adoption (VF-ADIN)

July 10, 2024 updated by: Centre Hospitalier St Anne
The purpose of this study is to determine the types of experiences faced by families in France who have adopted a child internationally. In addition, internationally adopted adolescents are invited to respond to questions about their own personal experiences.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Detailed Description

Microaggressions, or "unintended discrimination" related to adoption have been widely investigated in the USA. These microaggressions may relate to both adoptive status and country of origin, or both. However, the prevalence and qualitative characteristics of these events have been seldom studied in other countries. Differences in cultural norms and practices among countries might influence the type and frequency of microaggressions experienced by adopted children and their families. Brief anonymous questionnaires devised to elicit personal experiences related to microaggressions will be distributed by 4 clinical services serving this population (3 pediatric, 1 child psychiatric) and by 2 large adoptive family support networks to adoptive parents in France. Frequencies and relations between experience of micro-aggressions and other variables will be analyzed.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Observational

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
991

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Contact Backup

  • Name: Laurie MD MILLER
  • Phone Number: 33 0612222628

Study Locations

  • France
      • Dijon, France
        • Hospital Enfants CHU du BOCAGE
      • Paris, France, 75015
        • Hospital Necker
      • Paris, France, 75014
        • Hospital SAINTE ANNE
      • Versailles, France, 78000
        • Hospital MIGNOT

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

11 years and older (Child, Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

Adoptive parents, regardless of the age of their children, as well as adolescents who have been adopted internationally, directly.

Description

Inclusion Criteria:

Parents :

  1. Parents of an internationally adopted child, whose placement occurred at least 6 months ago
  2. Willing and able to complete a questionnaire

Adolescents :

  1. Internationally adopted adolescents who were placed at least 6 months ago
  2. Willing and able to complete a questionnaire

Exclusion Criteria:

Parents :

1. Unwilling or unable to complete the questionnaire

Adolescents :

  1. Parents are unwilling for child to participate
  2. Child is unwilling to participate
  3. Unable to understand the questions

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Number and type of micro-aggressions experienced by French families who have adopted internationally
Time Frame: parents respond to a questionnaire at a single time point, regarding their experience. Participation is hence limited to the 30 minutes required to complete the questionnaire.
Parents will respond to a questionnaire regarding their experiences of micro-aggressions as an adoptive family in France, enumerating the types of discrimination (if any) they have encountered, in what context or environment this occurred, and their feelings in response to these experiences. The types of micro-aggressions could include hearing derogatory comments about adoption in general, their child's country of origin or appearance, etc. Parents may also experience well-meaning but uninformed comments ("how much did she cost?") which are also experienced as micro-aggressions. Simple frequency statistics enumerating these experiences will be compiled. These will be compared to basic demographic indicators such as the country of origin of the child, the child's age at adoption, the child's current age, the time interval since adoption, etc.
parents respond to a questionnaire at a single time point, regarding their experience. Participation is hence limited to the 30 minutes required to complete the questionnaire.

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Number and type of micro-aggressions experienced by internationally adopted adolescents in France
Time Frame: Adolescents respond to a questionnaire at a single time point, regarding their experiences as an adopted person in France. Participation is hence limited to the 30 minutes required to complete the questionnaire.
Adolescents will respond to a questionnaire regarding their experiences of micro-aggressions as adopted individuals in France, enumerating the types of discrimination (if any) they have encountered, in what context or environment this occurred, and their feelings in response to these experiences. The types of micro-aggressions could include hearing derogatory comments about adoption in general, their country of origin or appearance, etc. Adolescents may also experience well-meaning but uninformed comments ("why did your real parents abandon you?") which are also experienced as micro-aggressions. Simple frequency statistics enumerating these experiences will be compiled. These will be compared to basic demographic indicators such as their country of origin, their age at adoption, their current age, the time interval since adoption, etc.
Adolescents respond to a questionnaire at a single time point, regarding their experiences as an adopted person in France. Participation is hence limited to the 30 minutes required to complete the questionnaire.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Centre Hospitalier St Anne

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Marie Odile MD PEROUSE DE MONTCLOS, Hospital SAINTE ANNE

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
October 9, 2017

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
June 6, 2018

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
June 6, 2018

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
March 20, 2018

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
August 23, 2018

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
August 24, 2018

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
July 11, 2024

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 10, 2024

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
July 1, 2024

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • D17-P16

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Discrimination, Racial

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings